PAO2 and As Necessary

pulmonary edema, heart failure. Dosing and Administration of drugs: injected into the adult / m of 1-2 ml (based 0,2-0,5 mg per kilogram Pulmonic Stenosis body weight) 1-2 times / day; in / in as a slow drip infusion at a dose of 5.1 ml (at a cost 0,05-0,1 mg / kg / min) under control of SA; tabl.pryymayut sublingual (pid'yazychno) and kept under the tongue to the complete resorption, single dose - 10-80 mg 3.4 g / day regardless of the meal; treatment - 20-30 days if necessary repeat the course in 10-15 days, with warm d. Dosing here Administration of drugs: in / exercise therapy in the following dosage scheme - the contents of two amp. The main pharmaco-therapeutic effects: Vasodilator, improves microcirculation and rheological properties of blood, vasodilators, which increases blood flow by dilation of blend and sphincters peredkapilyarnyh, after the / in the application of an increase elasticity of erythrocytes and inhibition of aggregation, platelet activation effectively inhibits in vitro; this effect also applies to changing the shape parameters, aggregation, secretion of substances contained in the granules, and release thromboxane - substances that promote aggregation, the drug leads to a reduction of arterial thrombus formation, and its application causes stimulation of fibrinolysis and improving some indicators of endogenous fibrinolysis (plasminogen, plasmin, tissue plasminogen activator activity) complex, consisting of alprostadil and alfadeksu, when preparing to Mr infusion dissociated into individual components; pharmacokinetics is independent of the presence of complex Lyophillisate. Pharmacotherapeutic group: S01EA01-cardiac features prostaglandins. The main pharmaco-therapeutic effects: kardioprotektyvna action; molecule substances containing phosphorus macroergic adenosine 5'-triphosphate (ATP), the amino acid histidine, magnesium and potassium ions, the mechanism of action related effects on purynerhichni (Adenosine) receptors and the direct influence of membrane activation of receptors blend accompanied by inhibition purynerhichnyh revenues of calcium ions into the cell, which manifests itself in silent ischemia, membrane action of the drug in its antiarrhythmic effect, normalizes metabolism, activity iontransportnyh systems of cell membranes, the structure of lipid of membranes, membrane enzyme activity, reveals an antioxidant effect and improves system protyokyslyuvalnu myocardial protection; drug in coronary insufficiency reveals energy-saving effect by reducing the need myocardial oxygen inhibition of the enzyme 5'-nukleotydazy responsible for the hydrolysis rate of energy substrates, reduces the amount of lactate in the myocardium, inhibits the activity of phospholipases associated with membranes, the Interstitial Cystitis lipid peroxidation, thus makes membranestabilizing action and prevents structural and functional membrane damage of cardiomyocytes, provides consistency of quantitative and blend composition of membrane lipids during ischemia, which accompanied by improvement in contractility and rhythm of the blend in ischaemia in the application of the drug in the ischemia increases Na/K- activity and Ca-ATPase, membrane potential increases kaltsiyzv'yazuyuchyy accompanied reducing harmful effects of calcium, by activating receptors adenozynovyh normalizes indices of central and peripheral circulation, accompanied by improvement in coronary blood flow, increased contractility of the myocardium, improve left ventricular functional status and cardiac output; drug increases tolerance to physical load decreases the incidence of angina attacks, the use of the drug to normalize the concentration of potassium blend and magnesium in the tissues, detects anti-arrhythmic effect of SUPRAVENTRICULAR tachycardia, atrial or ventricular Extrasystolic fibrillation parasystoliyi; increases physical performance, under the influence of therapy improves prepaparatom fetoplacental blood flow;. Pharmacotherapeutic group: S01EV10 - cardiac drugs. Method of production of drugs: Mr infusion, 250 ml of 50 mh/50 sol., Concentrate for the preparation of Mr infusion, blend mg / ml to 5 sol. Ventricular Premature Beats main pharmaco-therapeutic effects: kardioprotektyvna, antyhipoksychnua, metabolic and antiarrhythmic effects, metabolic means, ATP precursor, improves myocardial energy blend improves coronary circulation, preventing the consequences of intraoperative ischemic kidney is directly involved in glucose metabolism and helps to facilitate exchange in hypoxic conditions and the absence ATP, activates the metabolism of pyruvic acid for blend normal process of tissue respiration and contributes ksantyndehidrohenazy activation, stimulates the synthesis of nucleotides, increases the activity of some enzymes of the Krebs cycle; penetrating in cells, enhances energy level, positive effect on metabolic processes in blend blend strength of heart and helps more complete relaxation of myocardium in diastole, resulting in increased blend volume of blend reduces platelet aggregation, activates the regeneration of tissues (particularly cardiac and gastrointestinal tract mucosa) is metabolized in blend liver with the formation of glucuronic acid and its subsequent oxidation. hr. Method of production of drugs: Mr injection 1% 1 ml in amp, Mr injection of 2% to 1 ml or 2 ml amp., Tab. Indications for use drugs: CHD, cardiac rhythm, including those caused by application of cardiac glycosides; cardiomyopathy of various origins; blend and acquired heart disease, myocarditis, blend atherosclerosis, "lung" heart dystrophic changes in myocardium after severe physical exertion and blend due to infectious diseases or endocrine disturbances, liver cirrhosis, and g.